Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) is a commercial-stage biopharmaceutical company whose news flow centers on rare neuroendocrine diseases and MC4R pathway–targeted therapies. The company’s updates frequently highlight global commercial performance of its lead product IMCIVREE (setmelanotide), regulatory milestones, and clinical data across multiple rare obesity indications.
Investors following RYTM news can expect regular announcements on net product revenues from global sales of IMCIVREE, including the relative contributions from the United States and international markets. Rhythm also issues press releases on reimbursement developments, such as public reimbursement agreements for IMCIVREE in Canadian provinces and under federal programs for patients with Bardet-Biedl syndrome–related obesity.
Clinical and regulatory news is a major focus. Rhythm reports on Phase 3 trials like TRANSCEND in acquired hypothalamic obesity and EMANATE in genetically caused MC4R pathway diseases, as well as exploratory and Phase 2 studies in Prader-Willi syndrome and other rare conditions. Updates often include topline efficacy and safety data, cardiometabolic outcomes, and patient- and caregiver‑reported measures presented at scientific meetings.
Regulatory communications include FDA actions on supplemental New Drug Applications, PDUFA goal dates and extensions, and EMA validation of Type II variations to existing marketing authorizations. Rhythm also provides information on development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism.
For users tracking RYTM, this news feed offers a centralized view of earnings releases, clinical trial readouts, regulatory decisions and access milestones related to IMCIVREE and Rhythm’s broader rare disease pipeline.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a proposed public offering of $150 million of its common stock, with a potential additional $22.5 million if underwriters exercise their option. The offering is managed by Morgan Stanley, BofA Securities, Cowen, and Stifel, and is subject to market conditions. The shares will be offered under a shelf registration statement filed with the SEC. This move aims to bolster the company's capabilities to develop therapies for rare genetic obesity diseases.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced positive results from its Phase 2 Basket Study, demonstrating proof-of-concept for setmelanotide in patients with genetic obesity disorders. The study found that 34.3% of patients with HET obesity achieved significant weight loss. Updated data suggests that 100,000-200,000 patients in the U.S. could benefit from this treatment. Additionally, the pivotal Phase 3 trial for Bardet-Biedl Syndrome showed significant improvements in pediatric patients’ BMI-Z scores. Rhythm plans to initiate further studies to expand setmelanotide's application.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will host a virtual event on January 26, 2021, to present updates on its exploratory Phase 2 Basket Study and genetic sequencing efforts. Management will discuss data for setmelanotide in individuals with heterozygous obesity linked to genetic variants in POMC, PCSK1, or LEPR genes, as well as SRC1 and SH2B1 deficiency. The company has sequenced samples from approximately 37,500 individuals with severe obesity to enhance understanding and diagnosis of these conditions.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $100M. This voucher was granted by the FDA following the approval of IMCIVREE™ (setmelanotide) for chronic weight management in patients with genetic deficiencies causing severe obesity. The sale will provide non-dilutive capital to further develop setmelanotide, which has been approved for patients aged 6 and older. The upfront payment is conditioned on customary closing requirements, with an expected transaction completion following U.S. antitrust clearance.
On January 5, 2021, Pharvaris announced the appointment of David Meeker, M.D., as Chair of the Board and Robert Glassman, M.D., as Director. Dr. Meeker, currently CEO of Rhythm Pharmaceuticals (RYTM), brings extensive experience in rare disease drug development, while Dr. Glassman, a venture partner at OrbiMed Advisors, offers financial expertise. Pharvaris aims to enhance treatment options for hereditary angioedema through novel oral bradykinin-B2-receptor antagonists. The leadership changes are expected to bolster the company's strategic initiatives and clinical programs.
Rhythm Pharmaceuticals (RYTM) announced positive topline results from its pivotal Phase 3 trial of setmelanotide for Bardet-Biedl syndrome (BBS) and Alström syndrome. The study achieved its primary endpoint, with 34.5% of participants showing at least a 10% weight reduction. All responders were BBS patients, while none of the Alström participants met this endpoint. Rhythm plans to submit a supplemental New Drug Application (sNDA) to the FDA for BBS in the second half of 2021. The trial enrolled 32 BBS and 6 Alström patients, and setmelanotide was generally well tolerated with mild side effects.
Rhythm Pharmaceuticals (Nasdaq:RYTM) announced the appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors. Both leaders bring extensive experience in the pharmaceutical industry. Bedrosian, with a strong background in rare diseases, is EVP and CMO at Ultragenyx Pharmaceutical, while Tetrault has over two decades at AstraZeneca, including roles in executive leadership. Their addition is expected to enhance Rhythm's operational leadership and its commitment to developing therapies for rare genetic diseases of obesity.
Rhythm Pharmaceuticals announced FDA approval for IMCIVREE™ (setmelanotide) for chronic weight management in patients aged 6 or older with obesity caused by POMC, PCSK1, or LEPR deficiencies, confirmed by genetic testing. This marks the first therapy approved for these rare genetic diseases, expected to be commercially available in Q1 2021. The approval was based on two trials showing substantial weight loss in patients, alongside the issuance of a Rare Pediatric Disease Priority Review Voucher. The company aims to further explore the treatment's potential in related conditions.
Rhythm Pharmaceuticals announced interim Phase 2 data for setmelanotide, showing that its once-weekly formulation has safety and efficacy comparable to daily doses in treating obesity. Additionally, long-term extension study data indicated durable weight loss and decreased hunger over three years. The FDA has granted Breakthrough Therapy designation for setmelanotide, which targets rare genetic obesity disorders. The company aims for FDA approval for POMC and LEPR deficiency obesity by November 27, 2020, while maintaining a focus on developing precision therapies for patients with severe obesity.
Rhythm Pharmaceuticals reported its third-quarter 2020 financial results, highlighting key developments in its drug candidate setmelanotide. The FDA's PDUFA goal date for setmelanotide's approval for POMC and LEPR deficiency obesities is November 27, 2020. The company appointed Jennifer Chien and Yann Mazabraud to lead global commercial strategies. R&D expenses decreased to $23 million from $26.6 million year-over-year, while net loss narrowed to $33.8 million. As of September 30, 2020, cash reserves stood at $201.8 million, sufficient to fund operations through 2021.